Kling Bio Partners with Sanofi for Antibody Discovery Breakthroughs
Kling Bio Teams Up with Sanofi for Antibody Innovations
Kling Bio, a pioneering biotech company focused on creating antibody-based treatments, has embarked on an exciting journey by entering a collaboration with Sanofi. This partnership heralds a new chapter in the search for hard-to-find, immuno-functional antibodies derived from immortalized human B cells.
Unleashing Potential with Kling-Select
The collaboration aims to leverage Kling's innovative B cell immortalization and screening platform known as Kling-Select. This proprietary technology has demonstrated its capability in discovering highly potent neutralizing antibodies that could transform the landscape of disease prevention and treatment.
The Importance of Rapid Discovery
Kling-Select is not merely a technological advancement; it is a clinically validated platform that taps into patient-derived B cells for the discovery of effective antibodies and conserved viral epitopes. By doing so, it enhances the design of vaccines and therapeutics significantly. The function-first screening workflow utilized by Kling-Select accelerates the identification of rare immune targets, thus speeding up the creation of next-gen vaccine and treatment options.
Scientific Achievements and Broader Impact
The success stories associated with Kling-Select include validated antibody candidates for severe respiratory syncytial virus (RSV), COVID-19, and influenza. This track record underscores the platform's versatility and significant impact on scientific research and public health.
Goals of the Collaboration with Sanofi
The partnership’s primary objective is to identify and characterize monoclonal antibodies that exhibit strong neutralizing activity against human viral pathogens relevant to clinical settings. The insights drawn from this collaborative effort could pave the way for the development of next-generation antiviral therapies and inform vaccine designs that are more effective.
Insights from Leadership
Michael Koslowski, MD, the Chief Executive Officer of Kling Bio, shares his thoughts on the collaboration: "This collaboration with Sanofi emphasizes the vast potential of our Kling-Select platform to tackle global health challenges. By unlocking the discovery of human-derived antibodies, we aim to make significant strides in healthcare. Our combined expertise with Sanofi's vaccine development leadership positions us to advance revolutionary therapeutics and vaccines.”
About Kling Bio
Kling Bio is a privately-held biotech innovator that specializes in discovering and developing novel targets and therapeutic solutions. Headquartered in Amsterdam, the Company possesses a fully owned intellectual property portfolio that encompasses their proprietary platforms, Kling-Select and Kling-Evolve. These technologies facilitate the simultaneous discovery of fully human antibodies directly sourced from patient-derived B cells along with the targets they recognize.
Kling-Select and Immunological Advances
Kling-Select stands out due to its clinically validated B cell immortalization and screening technology. It identifies groundbreaking therapeutic antibody binders and targets from patients exhibiting outstanding clinical responses. This platform has played a crucial role in uncovering novel neutralizing antibodies for many infectious diseases, including COVID-19 and influenza. Recently, Kling-Select has also been used to analyze B cells infiltrating tumors from cancer patients, leading to a selection of novel antibody-target pairs.
The Role of Kling-Evolve
Kling-Evolve complements this by enabling ex vivo affinity maturation of B cell clones against specific targets. This technology becomes particularly advantageous for swiftly evolving neutralizing antibodies to counter emerging viral variants or improving the affinity and selectivity of antibody candidates in oncology.
Frequently Asked Questions
What is the focus of the collaboration between Kling Bio and Sanofi?
The collaboration aims to accelerate the discovery of neutralizing antibodies with the potential to develop novel antiviral therapeutics and vaccine candidates.
How does Kling-Select contribute to antibody discovery?
Kling-Select utilizes a clinically validated B cell immortalization technology to identify effective antibodies and viral epitopes, enhancing vaccine and therapeutic innovations.
Why is the discovery of neutralizing antibodies significant?
Neutralizing antibodies play a crucial role in providing immunity against viral infections, thus facilitating the development of effective vaccines and treatments.
What are Kling Bio's core technologies?
Kling Bio's core technologies include Kling-Select for antibody discovery and Kling-Evolve for refined antibody development against specified targets.
What past successes has Kling Bio achieved?
Kling Bio has successfully developed validated antibody candidates targeting RSV, COVID-19, and influenza, showcasing the broad applicability of its technologies.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
